GP88/PGRN Clinical Trials
Armed Forces Institute of Pathology
GP88/PGRN Tissue Brain Cancer Study
Cooperative Research and Development Agreement (CRADA) to study the potential role of GP88/PGRN in glioblastoma and neurodegenerative diseases.
Fox Chase Cancer Center
GP88/PGRN Blood and Tissue Breast & Lung Cancer Trial
Cooperative research agreement with Fox Chase Cancer Center to provide samples from breast and lung cancer patients and samples from healthy individuals for the Avon Foundation Early Detection Breast Cancer Study, which is correlating the expression levels of GP88/PGRN in tissue with GP88/PGRN levels in the blood of these two patient populations.
Greenebaum Cancer Center | University of Maryland
GP88/PGRN Blood Breast Cancer Study
Research agreement with the University of Maryland Greenebaum Cancer Center to collect blood samples from breast cancer patients for a study focused on measuring levels of GP88/PGRN over the course of treatment, recurrence, and mortality. The study is in its fourth year.
Greenebaum Cancer Center | University of Maryland
GP88/PGRN Blood Lung Cancer Study
Research agreement to collect blood samples from both newly diagnosed lung cancer patients and patients receiving ongoing treatment to correlate GP88/PGRN levels with treatment, recurrence, and mortality. The study is in its first year.
Olympus/Tokai University
GP88/PGRN Tissue Breast Cancer Study
Clinical study to correlate levels of GP88/PGRN expression with other biomarkers.
University of New Mexico
Breast Cancer Tissue Study
Research agreement with the New Mexico Cancer Care Alliance to collect tissue samples from breast cancer patients to correlate expression levels of GP88/PGRN in tissue with treatment, recurrence, and mortality.
Weinberg Cancer Institute | Franklin Square Hospital
GP88/PGRN Blood Breast Cancer Study
Research agreement to collect blood samples from breast cancer patients over the course of treatment for a longitudinal study focused on measuring levels of GP88/PGRN over the course of treatment. The study is entering its third year.
Armed Forces Institute of Pathology
GP88/PGRN Tissue Brain Cancer Study
Cooperative Research and Development Agreement (CRADA) to study the potential role of GP88/PGRN in glioblastoma and neurodegenerative diseases.
Fox Chase Cancer Center
GP88/PGRN Blood and Tissue Breast & Lung Cancer Trial
Cooperative research agreement with Fox Chase Cancer Center to provide samples from breast and lung cancer patients and samples from healthy individuals for the Avon Foundation Early Detection Breast Cancer Study, which is correlating the expression levels of GP88/PGRN in tissue with GP88/PGRN levels in the blood of these two patient populations.
Greenebaum Cancer Center | University of Maryland
GP88/PGRN Blood Breast Cancer Study
Research agreement with the University of Maryland Greenebaum Cancer Center to collect blood samples from breast cancer patients for a study focused on measuring levels of GP88/PGRN over the course of treatment, recurrence, and mortality. The study is in its fourth year.
Greenebaum Cancer Center | University of Maryland
GP88/PGRN Blood Lung Cancer Study
Research agreement to collect blood samples from both newly diagnosed lung cancer patients and patients receiving ongoing treatment to correlate GP88/PGRN levels with treatment, recurrence, and mortality. The study is in its first year.
Olympus/Tokai University
GP88/PGRN Tissue Breast Cancer Study
Clinical study to correlate levels of GP88/PGRN expression with other biomarkers.
University of New Mexico
Breast Cancer Tissue Study
Research agreement with the New Mexico Cancer Care Alliance to collect tissue samples from breast cancer patients to correlate expression levels of GP88/PGRN in tissue with treatment, recurrence, and mortality.
Weinberg Cancer Institute | Franklin Square Hospital
GP88/PGRN Blood Breast Cancer Study
Research agreement to collect blood samples from breast cancer patients over the course of treatment for a longitudinal study focused on measuring levels of GP88/PGRN over the course of treatment. The study is entering its third year.
© 2009 A&G Pharmaceutical, Inc. All Rights Reserved. | Terms of Use | Privacy
